1 / 3

Vaccine (Env)

Serum 1. 1. Vaccine (Env). Serum 2. 2. Serum 3. 3. Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment.

snana
Download Presentation

Vaccine (Env)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Serum 1 1 Vaccine (Env) Serum 2 2 Serum 3 3 Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment Stefanie Koch, Andreas Meyerhans, the GHRC and the CA-VIMC consortium within the CAVD; Department of Virology, University of the Saarland, Germany Neutralizing antibody assay - principle Use of HIV-1 Env-pseudoviruses in global HIV vaccine trials Serum assessment in neutralizing antibody assays using HIV-1 Env-pseudoviruses

  2. Standardized production and distribution of HIV pseudoviruses under GCLP conditions HIV pseudoviruses Shipping via World Courier Storage Production and quality control Pilot Study Partner Labs David Montefiori, Duke University, Durham Leigh Anne Eller, MUWRP, Uganda Bob Bailer, NVITAL, Gaithersburg Lynn Morris, NICD, South Africa Michael Seaman, Pre-clinical Neut. Antibody Laboratory, Boston Hagen von Briesen, HSC, Germany

  3. Highly congruent proficiency tests in 6 testing labs worldwide ID50 (DIL) HIV (+) Plasma IC50 µg/ml IC50 / IC80 for all three pseudovirus stocks deviates < 2 fold IC50 / IC80 for one of the three pseudovirus stocks deviates < 3 fold IC50 / IC80 for one of the three pseudovirus stocks deviates > 3 fold

More Related